Monday, December 23, 2024

Clover Signs COVID-19 Vaccine Supply Agreement with UNICEF

Clover Biopharmaceuticals, Ltd. a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that they have entered into a long-term agreement (LTA) with UNICEF for Clover to supply its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), to the COVAX Facility.

Also Read: Tune Therapeutics Launches with Pioneering Epigenomic Control Platform to Master Gene Networks, Treat Broad Range of Diseases

On June 30, 2021, Clover announced an Advance Purchase Agreement (APA) with GAVI, the Vaccine Alliance, to provide up to 414 million doses of SCB-2019 (CpG 1018/Alum) for procurement through the COVAX Facility, pending an Emergency Use Listing from the World Health Organization (WHO). The LTA will operationalize the APA and will allow participating countries of the COVAX Facility to access Clover’s COVID-19 vaccine candidate, through UNICEF, once the vaccine candidate receives an Emergency Use Listing by the WHO.

Joshua Liang, Chief Executive Officer of Clover Biopharmaceuticals said, “We look forward to working with UNICEF to expand the potential supply and distribution of our COVID-19 vaccine globally. Approximately less than 7% of the population in low-income countries have received access to COVID-19 vaccines to date and we remain committed to supporting equitable access to COVID-19 vaccines and helping populations in need around the world.”

Clover Biopharmaceuticals plans to submit conditional regulatory approval applications to the EMA, the NMPA and the WHO in the near-term and commence product launch post conditional approval.

About SCB-2019 (CpG 1018/Alum)

SCB-2019 (CpG 1018/Alum), Clover’s COVID-19 vaccine candidate, is anticipated to potentially be one of the first protein-based COVID-19 vaccines commercialized globally through the COVAX Facility. Employing the Trimer-Tag™ technology platform, Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein (referred to as S-Trimer™) based on the original strain of the SARS-CoV-2 virus. Clover created our COVID-19 vaccine candidate by combining SCB-2019 with Dynavax’s CpG 1018 advanced adjuvant and aluminum hydroxide (alum).

Subscribe Now

    Hot Topics